---
title: "BioMarin Pharmaceutical (BMRN) Gets a Buy from Jefferies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275774619.md"
description: "Jefferies analyst Akash Tewari has maintained a Buy rating on BioMarin Pharmaceutical (BMRN) with a price target of $113.00. Tewari, who focuses on the Healthcare sector, has an average return of 13.4% and a 56.55% success rate on his stock recommendations. Previously, Piper Sandler also rated the stock as a Buy with a price target of $84.00."
datetime: "2026-02-12T14:56:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275774619.md)
  - [en](https://longbridge.com/en/news/275774619.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275774619.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275774619.md) | [繁體中文](https://longbridge.com/zh-HK/news/275774619.md)


# BioMarin Pharmaceutical (BMRN) Gets a Buy from Jefferies

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $113.00.

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Tewari covers the Healthcare sector, focusing on stocks such as Neurocrine, Argenx Se, and Alkermes. According to TipRanks, Tewari has an average return of 13.4% and a 56.55% success rate on recommended stocks.

In a report released on February 6, Piper Sandler also maintained a Buy rating on the stock with a $84.00 price target.

### Related Stocks

- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [BioMarin Pharmaceutical Inc. (BMRN.US)](https://longbridge.com/en/quote/BMRN.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Faron Pharmaceuticals Ltd: Director Dealing](https://longbridge.com/en/news/281133676.md)
- [Glenmark Pharma to directly commercialize and distribute Ryaltris in U.S. effective](https://longbridge.com/en/news/281370208.md)
- [Glenmark goes direct with new US Ryaltris marketing plan](https://longbridge.com/en/news/281533476.md)
- [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/en/news/281015927.md)
- [Merck's Enlicitide Decanoate Shows Greater LDL-C Reduction Than Oral Non-Statins At 8 Weeks](https://longbridge.com/en/news/281051985.md)